Aktive Positionen von Naozumi Harada
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
United Immunity Co. Ltd.
United Immunity Co. Ltd. Pharmaceuticals: MajorHealth Technology United Immunity Co. Ltd. is a Japanese company that specializes in pipeline nano technology and immunity fusion technology, specifically in the field of cancer immunotherapy. The company is based in Tsu, Japan and was founded in 2017 by Naozumi Harada, who has been the CEO since then. The company's diverse products, including "nano immunotherapy," have shown promising clinical results and research in the treatment of sex cancer. The company is currently recruiting a researcher in the cancer immunotherapy field to analyze the action mechanism of nanotechnology applied cancer evaluation and drug evaluation using immunological methods. The company's focus is on the development of treatment for the cause of cold tumor type cancer through the understanding of tumor-associated macrophages. | Direktor/Vorstandsmitglied | 27.11.2017 | - |
Vorstandsvorsitzender | 27.11.2017 | - | |
Gründer | 27.11.2017 | - |
Karriereverlauf von Naozumi Harada
Statistik
International
Japan | 2 |
Operativ
Director/Board Member | 1 |
Chief Executive Officer | 1 |
Founder | 1 |
Sektoral
Health Technology | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Private Unternehmen | 1 |
---|---|
United Immunity Co. Ltd.
United Immunity Co. Ltd. Pharmaceuticals: MajorHealth Technology United Immunity Co. Ltd. is a Japanese company that specializes in pipeline nano technology and immunity fusion technology, specifically in the field of cancer immunotherapy. The company is based in Tsu, Japan and was founded in 2017 by Naozumi Harada, who has been the CEO since then. The company's diverse products, including "nano immunotherapy," have shown promising clinical results and research in the treatment of sex cancer. The company is currently recruiting a researcher in the cancer immunotherapy field to analyze the action mechanism of nanotechnology applied cancer evaluation and drug evaluation using immunological methods. The company's focus is on the development of treatment for the cause of cold tumor type cancer through the understanding of tumor-associated macrophages. | Health Technology |
- Börse
- Insiders
- Naozumi Harada
- Erfahrung